|
⚲
|
| Keyboard |
| Douglas Downs | |
|---|---|
| Firm | |
| Address | 1278 NW Farewell Dr Bend, OR 97703 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Deepow Capital Opportunity Fund I LP | 021-336755 | Director | 2.0 M of 10.0 M |
||
| Carbon Robotics Inc | 021-270156 | Executive Officer | 2.3 M of 2.3 M |
||
| Ankasa Regenerative Therapeutics Inc | 021-245063 | Executive Officer | 9.5 M of 20.0 M |
||
| Aristamd Inc | 021-223071 | Executive Officer | 2.1 M of 4.0 M |
||
| Synthorx Inc | 021-218758 | Executive Officer | 3.1 M of 6.2 M |
||
| Proximal Data Inc | 021-195616 | Executive Officer | 1.0 M of 1.0 M |
||
| Proximal Data Inc | 021-194258 | Executive Officer | 2.0 M of 2.0 M |
||
| Proximal Data Inc | 021-185995 | Executive Officer | 3.0 M of 3.0 M |
||
| Zacharon Pharmaceuticals Inc | 021-176129 | Executive Officer | 0.0 M of 0.0 M |
||
| Afraxis Inc | 021-176059 | Executive Officer | 0.0 M of 0.0 M |
||
| Revision Therapeutics Inc | 021-170338 | Executive Officer | 0.5 M of 5.0 M |
||
| Zacharon Pharmaceuticals Inc | 021-157289 | Executive Officer | 0.0 M of 0.0 M |
||
| RQX Pharmaceuticals Inc | 021-151693 | Executive Officer | 1.2 M of 7.0 M |
||
| Otonomy Inc | 021-147275 | Executive Officer | 24.2 M of 38.8 M |
||
| Otonomy Inc | 021-143212 | Executive Officer | 10.6 M of 26.0 M |
||
| Revision Therapeutics Inc | 021-141014 | Executive Officer | 2.3 M of 5.0 M |
||
| Revision Therapeutics Inc | 021-141016 | Executive Officer | 0.6 M of 0.6 M |
||
| Avalon Ventures Management LLC | |||||
| Avalon Ventures X LP | 021-183463 | Promoter | 201.6 M of 250.0 M |
26.3 M | |
| Avalon Ventures IX LP | 021-145167 | Promoter | 118.1 M of 200.0 M |
46.1 M | |